Keywords: neoadjuvant, xeloda, reduces, breast, tumor, size, ph

Neoadjuvant Xeloda reduces breast tumor size in Ph II trial

Article | 24 December 2007

Print This

Swiss drug major Roche says that interim data from the Phase II XeNA trial suggest that its product Xeloda (capecitabine) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in